Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of British Columbia

$27,000.00

Promoting efferocytosis to improve treatment outcomes after percutaneous coronary intervention

FY 2025-26

Summary
Improving treatment outcomes after stent implantation Over the course of our lives, fatty build-up (plaque) slowly forms inside the vessels that supply blood to our hearts. This build-up can block blood flow and cause dangerous heart attacks. To prevent this, more than 2 million people each year undergo a procedure in which doctors reopen the blocked vessel and insert a mesh tube called a stent to keep it open. Unfortunately, even after a stent is placed, plaque can form again in the same area, which puts patients at risk once more. Inflammation is known to play a major role in accelerating plaque formation, but a recent clinical trial showed that the use of an anti-inflammatory drug did not actually help. Our previous research may explain why: dead cells under the stent are the origins of long-term inflammation. Short-term inhibition of inflammation, as done in this previous clinical trial, did not remove dead cells. Therefore, long-term inflammation caused by these dead cells can still accelerate plaque formation. Previous studies from our lab has developed a strategy using a drug candidate to remove dead cells from the blood vessels and inhibit plaque formation. In this study, I will use my expertise in bioengineering and pathology to build novel models that mimic the stented vessels. I will use these models to prove that the clinical trial failed because the strategy they used cannot efficiently remove dead cells while the drug candidate we have can efficiently inhibit the formation of new plaques, leading to better patient recovery after stent procedures.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572851
Name
Buenaventura Gaea Louise V
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Promoting efferocytosis to improve treatment outcomes after percutaneous coronary intervention
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Atherogenesis; Atherosclerosis; Disease Modelling; Drug Eluting Stents; Drug Repurposing; Efferocytosis; Inflammation; Neoatherosclerosis; Percutaneous Coronary Intervention; Secondary Prevention
Abstract
Improving treatment outcomes after stent implantation Over the course of our lives, fatty build-up (plaque) slowly forms inside the vessels that supply blood to our hearts. This build-up can block blood flow and cause dangerous heart attacks. To prevent this, more than 2 million people each year undergo a procedure in which doctors reopen the blocked vessel and insert a mesh tube called a stent to keep it open. Unfortunately, even after a stent is placed, plaque can form again in the same area, which puts patients at risk once more. Inflammation is known to play a major role in accelerating plaque formation, but a recent clinical trial showed that the use of an anti-inflammatory drug did not actually help. Our previous research may explain why: dead cells under the stent are the origins of long-term inflammation. Short-term inhibition of inflammation, as done in this previous clinical trial, did not remove dead cells. Therefore, long-term inflammation caused by these dead cells can still accelerate plaque formation. Previous studies from our lab has developed a strategy using a drug candidate to remove dead cells from the blood vessels and inhibit plaque formation. In this study, I will use my expertise in bioengineering and pathology to build novel models that mimic the stented vessels. I will use these models to prove that the clinical trial failed because the strategy they used cannot efficiently remove dead cells while the drug candidate we have can efficiently inhibit the formation of new plaques, leading to better patient recovery after stent procedures.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Buenaventura, Gaea Louise V
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~